Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Hypercholesterolemia | Research

Prevalence of chronic kidney diseases and its determinants among Iranian adults: results of the first phase of Shahedieh cohort study

Authors: Ali Dehghani, Sadegh Alishavandi, Nader Nourimajalan, Hossein Fallahzadeh, Vahid Rahmanian

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Chronic kidney disease (CKD) is one of the major global causes of mortality, described as the most neglected chronic disease. This study aimed to determine the prevalence and determinants of CKD in the setting of the Shahedieh cohort study in Yazd, Iran.

Methods

This cross-sectional study was conducted on adults in the baseline phase of the Shahedieh cohort study in Yazd, Iran. In this study, 9781 participants aged 30–73-year-old were investigated. The data used in this study included demographic and clinical variables and blood samples. Adjusted odds ratios were employed using multivariate logistic regression; meanwhile, population attributable risks for CKD were calculated and reported.

Results

CKD prevalence was 27.5% (95%CI: 26.57–28.34) in all participants, 24% in male, and 30.3% in female. The results of multivariate logistic regression analysis identified age (OR = 1.89, 95%CI:1.082–1.96), women (OR = 1.62, 95%CI: 1.45–1.79), BMI ≥ 30 (OR = 1.40,95%CI: 1.20–1.62), diabetes (OR = 1.38, 95%CI: 1.22–1.57), hypertriglyceridemia(OR = 1.20, 95%CI: 1.01–1.43), history of cardiovascular disease (OR = 1.20, 95%CI: 1.01–1.43), hypertension (OR = 1.18, 95%CI: 1.04–1.33), smoking (OR = 1.17, 95% CI: 1.02–1.33), LDL ≥ 130 (OR = 1.15, 95%CI: 1.01–1.31), history of kidney stone (OR = 1.14, 95%CI: 1.01–1.32) and hypercholesterolemia (OR = 1.14, 95%CI: 1.01–1.32) as risk factors for CKD. Among individual factors, obesity (11.25%), Hypertriglyceridemia (9.21%), LDL ≥ 130 (7.12%) had the greatest Population-Attributable Fraction, followed by Hypercholesterolemia (5.2%), diabetes (5.05%), smoking (3.73%) and high blood pressure (2.82%).

Conclusion

The results showed that the main determinants of CKD are potentially modifiable risk factors. Therefore, implementing early detection and screening programs in people at risk as well as preventive measures such as lifestyle modification programs and risk factors controlling can prevent the disease.
Literature
1.
Radhakrishnan J, Remuzzi G, Saran R, Williams DE, Rios-Burrows N, Powe N, et al. Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney Int. 2014;86(2):246–50.PubMedPubMedCentralCrossRef
2.
Ene-Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health. 2016;4(5):e307–e19.PubMedCrossRef
3.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef
4.
Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common complications. Am Fam Physician. 2004;70(10):1921–8.PubMed
5.
Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709–33.CrossRef
6.
Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88(5):950–7.PubMedPubMedCentralCrossRef
7.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.PubMedCrossRef
8.
White SL, Chadban SJ, Jan S, Chapman JR, Cass A. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ. 2008;86:229–37.PubMedPubMedCentralCrossRef
9.
Raimann JG, Riella MC, Levin NW. International Society of Nephrology’s 0by25 initiative (zero preventable deaths from acute kidney injury by 2025): focus on diagnosis of acute kidney injury in low-income countries. Clin Kidney J. 2018;11(1):12–9.PubMedCrossRef
10.
Outcomes KDIG, Group CW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):1–150.
11.
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.PubMedPubMedCentralCrossRef
12.
Moazzeni SS, Arani RH, Hasheminia M, Tohidi M, Azizi F, Hadaegh F. High incidence of chronic kidney disease among Iranian diabetic adults: using CKD-EPI and MDRD equations for estimated glomerular filtration rate. Diabetes Metab J. 2021;45(5):684–97.PubMedPubMedCentralCrossRef
13.
Noble R, Taal MW. Epidemiology and causes of chronic kidney disease. Medicine. 2019;47(9):562–6.CrossRef
14.
Taal M, Brenner B. Predicting initiation and progression of chronic kidney disease: developing renal risk scores. Kidney Int. 2006;70(10):1694–705.PubMedCrossRef
15.
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802.PubMedCrossRef
16.
Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al. Prospective epidemiological research studies in Iran (the PERSIAN cohort study): rationale, objectives, and design. Am J Epidemiol. 2018;187(4):647–55.PubMedCrossRef
17.
Ren H, Zhang L, Liu Z, Zhou X, Yuan G. Sleep duration and apolipoprotein B in metabolically healthy and unhealthy overweight/obese phenotypes: a cross-sectional study in Chinese adults. BMJ Open. 2019;9(2):e023817.PubMedPubMedCentralCrossRef
18.
National Cholesterol Education Program (US). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.
19.
Sepanlou SG, Barahimi H, Najafi I, Kamangar F, Poustchi H, Shakeri R, et al. Prevalence and determinants of chronic kidney disease in northeast of Iran: results of the Golestan cohort study. PLoS One. 2017;12(5):e0176540.PubMedPubMedCentralCrossRef
20.
Ryan H, Trosclair A, Gfroerer J. Adult current smoking: differences in definitions and prevalence estimates–NHIS and NSDUH, 2008. J Environ Public Health. 2012;2012:1–11.CrossRef
21.
Hemayatkhah M, Ghaffari S, Masjedi MR, Rahmanian V. Frequency of tobacco use among students in Varamin city: results of the first phase of the PAD project study (tobacco use prevention in schools). Koomesh. 2021;23(6):777–84.
22.
Hemayatkhah M, Rahmanian V, Rahmanian K, Haghdoost A. Population size estimation of groups at high risk of HIV/AIDS in men, using network scale up in south of Iran, 2017. J Isfahan Med Sch. 2019;36(512):1162–9.
23.
Szklo M, Nieto FJ. Epidemiology: beyond the basics. USA: Jones & Bartlett Publishers; 2014.
24.
Graubard BI, Fears TR. Standard errors for attributable risk for simple and complex sample designs. Biometrics. 2005;61(3):847–55.PubMedCrossRef
25.
Safarinejad MR. The epidemiology of adult chronic kidney disease in a population-based study in Iran: prevalence and associated risk factors. J Nephrol. 2009;22(1):99.PubMed
26.
Najafi I, Attari F, Islami F, Shakeri R, Malekzadeh F, Salahi R, et al. Renal function and risk factors of moderate to severe chronic kidney disease in Golestan Province, northeast of Iran. PLoS One. 2010;5(12):e14216.PubMedPubMedCentralCrossRef
27.
Najafi I, Shakeri R, Islami F, Malekzadeh F, Salahi R, Gharavi M, et al. Prevalence of chronic kidney disease and its associated risk factors: the first report from Iran using both micro albuminuria and urine sediment. Arch Iran Med. 2012;15(2):70–5.PubMed
28.
Naghibi M, Mojahedi MJ, Jarrahi L, Emadzadeh A, Ahmadi R, Emadzadeh M, et al. Prevalence of chronic kidney disease and its risk factors in Gonabad, Iran. Iran J Kidney Dis. 2015;9(6):449.PubMed
29.
Bakhshayeshkaram M, Roozbeh J, Heydari ST, Honarvar B, Dabbaghmanesh MH, Ghoreyshi M, et al. A population-based study on the prevalence and risk factors of chronic kidney disease in adult population of shiraz, Southern Iran. Galen Med J. 2019;8:e935.PubMedPubMedCentralCrossRef
30.
Rao MK. The utility of a National Surveillance Network to estimate CKD prevalence and identify high-risk populations in primary care. Kidney Int Rep. 2019;4(4):513–5.PubMedPubMedCentralCrossRef
31.
Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Netw Open. 2019;2(12):e1918169.PubMedPubMedCentralCrossRef
32.
Rowe JW, Andres R, Tobin JD. Letter: age-adjusted standards for creatinine clearance. Ann Intern Med. 1976;84(5):567–9.PubMedCrossRef
33.
Goncalves GMR, Silva EN. Cost of chronic kidney disease attributable to diabetes from the perspective of the Brazilian unified health system. PLoS One. 2018;13(10):e0203992.PubMedPubMedCentralCrossRef
34.
Poggio ED, Rule AD, Tanchanco R, Arrigain S, Butler RS, Srinivas T, et al. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int. 2009;75(10):1079–87.PubMedPubMedCentralCrossRef
35.
Blake GM, Sibley-Allen C, Hilton R, Burnapp L, Moghul MR, Goldsmith D. Glomerular filtration rate in prospective living kidney donors. Int Urol Nephrol. 2013;45(5):1445–52.PubMedCrossRef
36.
Chen K, Gosmanova E, Curhan G, Rejnmark L, Mu F, Swallow E, et al. MON-522 Risk of Chronic Kidney Disease (CKD) and Its Progression in Patients with Chronic Hypoparathyroidism (HypoPT). J Endocr Soc. 2019;3(Suppl 1):MON–522.PubMedCentral
37.
Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55(1):66–76.PubMedCrossRef
38.
Khajehdehi P, Malekmakan L, Pakfetrat M, Roozbeh J, Sayadi M. Prevalence of chronic kidney disease and its contributing risk factors in southern Iran a cross-sectional adult population-based study; 2014.
39.
Yu MK, Katon W, Young BA. Associations between sex and incident chronic kidney disease in a prospective diabetic cohort. Nephrology. 2015;20(7):451–8.PubMedCrossRef
40.
Wang J, Niratharakumar K, Gokhale K, Tahrani AA, Taverner T, Thomas GN, et al. Obesity without metabolic abnormality and incident CKD: a population-based British cohort study. Am J Kidney Dis. 2022;79(1):24–35 e1.PubMedCrossRef
41.
42.
Alarabi A, Nyström S-O, Ståhle E. Acute renal failure and outcome of continuous arteriovenous hemodialysis (CAVHD) and continuous hemofiltration (CAVH) in elderly patients following cardiovascular surgery. Geriatr Nephrol Urol. 1997;7(1):45–9.PubMedCrossRef
43.
Noshad S, Afarideh M, Heidari B, Mechanick JI, Esteghamati A. Diabetes care in Iran: where we stand and where we are headed. Ann Global Health. 2015;81(6):839–50.CrossRef
44.
Akbari F, Azadbakht L. A systematic review on diet quality among Iranian youth: focusing on reports from Tehran and Isfahan. Arch Iran Med. 2014;17(8):0.
45.
Rezaei S, Mahmoudi Z, Sheidaei A, Aryan Z, Mahmoudi N, Gohari K, et al. Salt intake among Iranian population: the first national report on salt intake in Iran. J Hypertens. 2018;36(12):2380–9.PubMedCrossRef
46.
Bach KE, Kelly JT, Palmer SC, Khalesi S, Strippoli GF, Campbell KL. Healthy dietary patterns and incidence of CKD: a meta-analysis of cohort studies. Clin J Am Soc Nephrol. 2019;14(10):1441–9.PubMedPubMedCentralCrossRef
47.
Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74(1):120–31.PubMedCrossRef
48.
Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015;22(2):88–95.PubMedCrossRef
49.
Lertpimonchai A, Rattanasiri S, Tamsailom S, Champaiboon C, Ingsathit A, Kitiyakara C, et al. Periodontitis as the risk factor of chronic kidney disease: mediation analysis. J Clin Periodontol. 2019;46(6):631–9.PubMedPubMedCentralCrossRef
50.
Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita study. Stroke. 2009;40(8):2674–9.PubMedCrossRef
51.
Consortium CKDP. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–81.CrossRef
52.
Van Der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341–52.PubMedCrossRef
53.
Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014;3(3):99–104.PubMedPubMedCentral
54.
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–72.PubMedPubMedCentralCrossRef
55.
Podkowińska A, Formanowicz D. Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease. Antioxidants. 2020;9(8):752.PubMedCentralCrossRef
56.
Vupputuri S, Soucie JM, McClellan W, Sandler DP. History of kidney stones as a possible risk factor for chronic kidney disease. Ann Epidemiol. 2004;14(3):222–8.PubMedCrossRef
57.
Kummer AE, Grams M, Lutsey P, Chen Y, Matsushita K, Köttgen A, et al. Nephrolithiasis as a risk factor for CKD: the atherosclerosis risk in communities study. Clin J Am Soc Nephrol. 2015;10(11):2023–9.PubMedPubMedCentralCrossRef
58.
59.
Yao KH, Guehi MC, Konan SD, Diopoh SP, Moudachirou MA, Sanogo S, et al. Prevalence and risk factors for chronic kidney disease in general population of Yopougon (Côte d’ivoire); a cross-sectional study. J Renal Inj Prev. 2017;7(1):27–32.
60.
Saber A, Tahami AN, Najafipour H, Azmandian J. Assessment of prevalence of chronic kidney disease and its predisposing factors in Kerman city. Nephro-Urology Monthly. 2017;9(2):1–8.CrossRef
61.
Wagner S, Merkling T, Metzger M, Bankir L, Laville M, Frimat L, et al. CKD-REIN study group. Water intake and progression of chronic kidney disease: the CKD-REIN cohort study. Nephrol Dial Transplant. 2022;37(4):730-9.
62.
Clark WF, Sontrop JM, Huang S-H, Gallo K, Moist L, House AA, et al. The chronic kidney disease water intake trial (WIT): results from the pilot randomised controlled trial. BMJ Open. 2013;3(12):e003666.PubMedPubMedCentralCrossRef
63.
Lebov JF, Valladares E, Peña R, Peña EM, Sanoff SL, Cisneros EC, et al. A population-based study of prevalence and risk factors of chronic kidney disease in León, Nicaragua. Can J Kidney Health Dis. 2015;2:41.CrossRef
64.
Sontrop JM, Dixon SN, Garg AX, Buendia-Jimenez I, Dohein O, Huang S-HS, et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol. 2013;37(5):434–42.PubMedCrossRef
Metadata
Title
Prevalence of chronic kidney diseases and its determinants among Iranian adults: results of the first phase of Shahedieh cohort study
Authors
Ali Dehghani
Sadegh Alishavandi
Nader Nourimajalan
Hossein Fallahzadeh
Vahid Rahmanian
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02832-5

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue

Research article

Association of plasma neutrophil gelatinase-associated lipocalin and thoracic aorta calcification in maintenance hemodialysis patients with and without diabetes

Research

Impact of telehealth interventions added to peritoneal dialysis-care: a systematic review

Research

Association of accelerometer-measured physical activity with kidney function in a Japanese population: the DOSANCO Health Study

Correction

Correction: Elevated triglycerides and reduced high-density lipoprotein cholesterol are independently associated with the onset of advanced chronic kidney disease: a cohort study of 911,360 individuals from the United Kingdom

Research

Serum homocysteine is associated with tubular interstitial lesions at the early stage of IgA nephropathy

Research

Healthcare provider perspectives on integrating peer support in non-dialysis-dependent chronic kidney disease care: a mixed methods study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits